Lumosa Therapeutics, a public traded company in Taipei Exchange (6535.TWO), is dedicated to the development of innovative new drugs for the treatment of neurological and oncological diseases of unmet medical needs. The company is actively engaged in scientific in-licensing and new drug development under the “reSEARCH and DEVELOPMENT” model. This model is executed by a highly capable and experienced cross-functional teams of translational research, CMC, preclinical, clinical development, project management, regulatory affairs, intellectual property and business development experts. Current products/pipeline include Naldebain®, a long long-acting analgesic injection, launched in Taiwan in 2017, Singapore in 2020, Thailand in 2021, Malaysia in 2022, and Ukraine and Brunei in 2023; LT3001, an NCE for the treatment of acute ischemic stroke currently under phase II clinical trial in the US and Taiwan; LT2003, tumor-targeting enzyme prodrug; and LT5001, a novel topical drug for uremic pruritus. The photo of Chingshui Cliff is used for the home page. The coastal cliff, located in Taroko National Park, averages 800 meters above sea level. The geo-formation of the cliff involves three continental plates: the Eurasian Plate, the Philippine Sea Plate, and the Pacific Plate. The collision of these three plates is what has led to the formation of the cliff. The sudden rise and majestic scene of the Chingshui Cliff represent our company's strive to achieve excellence and stand out in our industry.
